NFKB1 and Waldenstrom macroglobulinemia: To date, there are very few FDA-approved NF-κB inhibitors, and most focus on blood cancers; e.g. bortezomib is a proteasome inhibitor not specific to NF-κB, and used on mantle cell lymphoma, multiple myeloma, and Waldenström macroglobulinemia.